PrintThe Burrill Report
Steve Burrill sits down for an informal and frank discussion with Eli Lilly CEO John Lechleiter about how the company will navigate its way through one of the steepest patent cliffs in the industry.
November 5, 2010
December 31, 2010
http://www.burrillreport.com/article-a_conversation_with_eli_lillys_john_lechleiter.html
INSIGHT
A Conversation with Eli Lilly's John Lechleiter
InSight with Steve Burrill: November 5, 2010[Please login to post comments]
- The Curtain Rises on 2011
Podcast: January 10, 2011 Read More - Life Sciences Venture Capital Flows in 2010
Regional breakdown shows most money goes to San Francisco Bay Area, but Boston area sees greatest gains. Read More - Xoma Lands Deep-Pocketed French Partner
Servier to pay up to $505 million for experimental antibody to treat diabetes and other conditions. Read More - When NICE News Isn’t So Nice for Roche
UK advisory body will consider whether to allow the use of Avastin to treat wet age-related macular degeneration. Read More - Policy Victories of 2010 and the Battles Ahead in the New Year
Podcast: January 3, 2011 Read More - Life Sciences Companies Raise Record Amounts of Capital
Venture financings more than double while public companies go for debt. Read More - A Conversation About the Future of Molecular Diagnostics
InSight with Steve Burrill: December 7, 2010 Read More - A View of the State of the Industry
Insight with Steve Burrill: October 25, 2010 Read More - Stem Cell Research Under Attack
InSight with Steve Burrill: August 30, 2010 Read More - Two Wrongs
Critics of the nation’s move toward government-run healthcare are misreading the FDA’s Avastin decision. Read More
.gif)
.gif)
| Burrill Select | NSDQ Biotech | BIOTECH |
923.97
-4.82 (-0.52%)
| Index | Last | Change (%) |
|---|---|---|
| Burrill Select | 923.97 | -4.82 (-0.52%) |
| NSDQ Biotech | 837.68 | -5.20 (-0.62%) |
| BIOTECH | 1052.01 | - (+0.00) |
| Amex Pharm | 271.23 | - (+0.00) |
| Nasdaq | 2257.04 | -20.64 (-0.91%) |
| S&P 500 | 1089.41 | - (+0.00) |
| NYSE | 6791.57 | -101.72 (-1.48%) |
| RUS 2K | 661.61 | -8.90 (-1.33%) |
Quotes delayed at least 20 mins.
Get Quote
 |
- Health Care Law Ruled Unconstitutional
The New york Times - Bayer to Spend $4.1 Billion on Research in 2011 as Xarelto Trials Near End
Bloomberg - Sanofi's chief gets U.S. lobby role as Kindler exits
Reuters - Pfizer’s Chairman and Chief Retires Unexpectedly
The New York Times - Arsenic-eating bacteria point to new life forms
The Scientist - Merck to buy SmartCells to gain diabetes product
Reuters - Overweight People, Not Just Obese, More Likely to Die Sooner, Study Says
Bloomberg - Orexigen Options Suggest Contrave Diet Pill May Avoid Arena, Vivus Delays
Bloomberg - Biosimilars will be challenging for FDA, speakers say
The Hill - EU guidelines clear way for biosimilar antibodies
Reuters